Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| AMGN | Amgen Inc. | -2.13% | 199.08 | 1.3% | $749.78m | |
| GILD | Gilead Sciences, Inc. | -2.66% | 62.51 | 0.9% | $372.82m | |
| CELG | Celgene Corporation | -1.80% | 93.99 | 1.3% | $323.19m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -6.61% | 115.33 | 2.0% | $295.67m | |
| ILMN | Illumina, Inc. | -3.17% | 279.44 | 3.5% | $272.03m | |
| BIIB | Biogen Inc. | -2.68% | 225.85 | 1.3% | $258.17m | |
| VRTX | Vertex Pharmaceuticals Incorporated | -2.20% | 180.18 | 1.9% | $251.48m | |
| EXAS | Exact Sciences Corporation | -0.77% | 116.96 | 24.1% | $238.08m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -2.77% | 286.85 | 2.6% | $193.57m | |
| A | Agilent Technologies, Inc. | -3.01% | 69.58 | 1.6% | $188.95m | |
| SRPT | Sarepta Therapeutics, Inc. | -1.54% | 93.61 | 14.7% | $184.96m | |
| BMRN | BioMarin Pharmaceutical Inc. | -2.12% | 75.76 | 4.3% | $97.12m | |
| INCY | Incyte Corporation | -4.27% | 81.91 | 2.5% | $90.56m | |
| GHDX | Genomic Health, Inc. | -0.35% | 73.26 | 1.8% | $81.69m | |
| NBIX | Neurocrine Biosciences, Inc. | 0.36% | 97.59 | 5.0% | $71.75m |
Company Profile
NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA.